News

Medical Device Network on MSN4d
FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients
Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...
GlobalData on MSN1mon
Medtronic announces two-year trial outcomes of Evolut TAVR
In the international, multi-centre trial, the Evolut TAVR demonstrated “continued superior” valve performance, according to ...
Seeking Alpha1mon
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...
Healio4d
FDA approves first TAVR platform to treat severe asymptomatic aortic stenosis
Edwards Lifesciences’ TAVR platform is the first to be approved in this population. Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for ...
TCTMD2y
Episode 15: "X4 vs FX: New TAVR transformations"
Dr. George and the Columbia Valve team discussed new technology from the two largest structural heart companies, the Edwards SAPIEN X4 and the Medtronic Evolut FX. Receive the the latest news, ...
Nasdaq4d
Edwards Lifesciences Says FDA Approved TAVR Therapy For Asymptomatic Severe Aortic Stenosis
(RTTNews) - Edwards Lifesciences Corp. (EW) Thursday said that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 ...
Pharmabiz1mon
Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve ...
Yahoo Finance4d
FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients
holding more than 60% of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards’ SAPIEN ...
Medindia1mon
Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...